Index -
P/E -
EPS (ttm) -1.20
Insider Own 23.53%
Shs Outstand 93.09M
Perf Week 10.92%
Market Cap 574.45M
Forward P/E -
EPS next Y -0.77
Insider Trans 0.84%
Shs Float 86.48M
Perf Month -9.12%
Income -110.57M
PEG -
EPS next Q -0.21
Inst Own 33.73%
Short Float 9.98%
Perf Quarter 14.67%
Sales 5.72M
P/S 100.43
EPS this Y 29.72%
Inst Trans 3.16%
Short Ratio 5.89
Perf Half Y 313.01%
Book/sh 1.89
P/B 2.68
EPS next Y 9.29%
ROA -38.58%
Short Interest 8.63M
Perf Year 306.40%
Cash/sh 1.01
P/C 5.05
EPS next 5Y 23.30%
ROE -49.08%
52W Range 1.11 - 6.72
Perf YTD 20.95%
Dividend Est. -
P/FCF -
EPS past 5Y -46.78%
ROI -59.27%
52W High -24.40%
Beta 2.40
Dividend TTM -
Quick Ratio 4.08
Sales past 5Y 37.94%
Gross Margin -144.82%
52W Low 357.20%
ATR (14) 0.42
Dividend Ex-Date -
Current Ratio 4.08
EPS Y/Y TTM -4.03%
Oper. Margin -1638.34%
RSI (14) 50.47
Volatility 7.32% 8.06%
Employees 156
Debt/Eq 0.09
Sales Y/Y TTM -0.50%
Profit Margin -1933.65%
Recom 1.33
Target Price 8.60
Option/Short Yes / Yes
LT Debt/Eq 0.06
EPS Q/Q -19.28%
Payout -
Rel Volume 0.36
Prev Close 4.98
Sales Surprise -62.44%
EPS Surprise -17.65%
Sales Q/Q -78.29%
Earnings May 14 BMO
Avg Volume 1.47M
Price 5.08
SMA20 -2.57%
SMA50 -1.33%
SMA200 66.96%
Trades
Volume 536,637
Change 2.01%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-14-24 Initiated
Scotiabank
Sector Outperform
$13
Dec-05-23 Initiated
KeyBanc Capital Markets
Overweight
$3
May-04-23 Initiated
H.C. Wainwright
Buy
$4
Aug-12-22 Downgrade
JP Morgan
Overweight → Underweight
Jul-18-22 Initiated
Truist
Buy
$8
Mar-02-22 Resumed
Cowen
Market Perform
Feb-01-22 Initiated
Berenberg
Buy
$28
Nov-10-21 Downgrade
BofA Securities
Neutral → Underperform
$10
Oct-15-21 Resumed
Cowen
Market Perform
Aug-16-21 Initiated
Stifel
Hold
$28
Aug-16-21 Initiated
Credit Suisse
Outperform
$40
Aug-16-21 Initiated
Cowen
Market Perform
Aug-16-21 Initiated
BofA Securities
Neutral
$26
Show Previous Ratings
Apr-16-24 08:00AM
Apr-10-24 11:07AM
Mar-28-24 04:05PM
Mar-23-24 05:31AM
Mar-21-24 02:52PM
07:30AM
Loading…
07:30AM
Mar-12-24 05:34PM
Mar-06-24 06:34AM
Mar-01-24 04:01PM
06:49AM
Feb-27-24 10:20PM
04:01PM
Feb-21-24 07:30AM
Feb-20-24 08:00AM
Feb-05-24 09:40AM
07:30AM
Loading…
Jan-10-24 07:30AM
Jan-08-24 07:00AM
Jan-03-24 08:00AM
Dec-28-23 08:00AM
Dec-20-23 07:30AM
Dec-05-23 08:11AM
Dec-04-23 07:30AM
06:18AM
Dec-03-23 01:27AM
01:22AM
12:21AM
12:00AM
Nov-15-23 08:00AM
Nov-14-23 06:15PM
04:05PM
02:16AM
Loading…
02:16AM
Oct-26-23 08:00AM
Sep-21-23 08:00AM
Sep-06-23 08:00AM
Aug-28-23 04:05PM
Aug-14-23 03:51PM
08:02AM
08:00AM
Aug-10-23 08:00AM
Aug-01-23 08:00AM
Jul-26-23 08:00AM
Jun-15-23 08:00AM
Jun-07-23 09:32AM
Jun-06-23 08:00AM
May-15-23 05:45PM
04:05PM
May-11-23 08:00AM
May-03-23 10:00AM
Apr-06-23 08:00AM
Apr-04-23 08:00AM
Apr-01-23 08:25AM
Mar-30-23 04:05PM
Mar-23-23 08:00AM
Mar-07-23 08:00AM
06:08AM
Feb-28-23 08:00AM
Feb-21-23 08:00AM
Feb-09-23 08:00AM
Feb-08-23 08:00AM
Jan-10-23 10:36AM
10:00AM
(American City Business Journals)
08:00AM
Jan-08-23 03:13PM
Dec-29-22 07:17AM
Dec-28-22 08:00AM
Nov-23-22 08:00AM
Nov-17-22 08:00AM
Nov-09-22 10:47AM
(American City Business Journals)
09:15AM
08:00AM
Nov-02-22 04:05PM
08:00AM
Oct-26-22 08:00AM
Oct-04-22 07:00AM
Sep-28-22 06:44AM
Sep-01-22 08:00AM
Aug-24-22 07:00AM
Aug-15-22 04:00PM
(American City Business Journals)
Aug-11-22 09:15AM
08:00AM
Aug-10-22 10:50AM
(American City Business Journals) +7.69%
08:19AM
Aug-02-22 11:17AM
Aug-01-22 08:00AM
Jul-26-22 02:23PM
(American City Business Journals)
Jul-22-22 07:25AM
Jul-21-22 07:00AM
Jul-14-22 07:05AM
Jul-07-22 07:05AM
Jun-16-22 05:48PM
(American City Business Journals) -5.80%
Jun-14-22 06:06PM
(American City Business Journals) +5.06%
Jun-13-22 11:37AM
(American City Business Journals)
11:37AM
(American City Business Journals)
May-30-22 06:18AM
May-12-22 02:29PM
(American City Business Journals)
May-11-22 08:00AM
May-03-22 08:55AM
Apr-28-22 07:00AM
Apr-26-22 06:23PM
(American City Business Journals) -11.28%
Apr-20-22 08:03AM
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Redmile Group, LLC Director Mar 01 '24 Buy 4.50 222,222 999,999 8,253,316 Mar 05 09:30 PM
Index RUT
P/E -
EPS (ttm) -1.63
Insider Own 12.59%
Shs Outstand 113.82M
Perf Week 6.84%
Market Cap 462.11M
Forward P/E -
EPS next Y -1.81
Insider Trans -0.24%
Shs Float 99.88M
Perf Month -41.75%
Income -160.93M
PEG -
EPS next Q -0.48
Inst Own 83.89%
Short Float 18.94%
Perf Quarter -37.73%
Sales 63.53M
P/S 7.27
EPS this Y -17.52%
Inst Trans -2.76%
Short Ratio 7.17
Perf Half Y 110.36%
Book/sh 3.74
P/B 1.09
EPS next Y 6.23%
ROA -26.56%
Short Interest 18.92M
Perf Year -35.76%
Cash/sh 2.77
P/C 1.47
EPS next 5Y -
ROE -37.76%
52W Range 1.63 - 8.83
Perf YTD 8.56%
Dividend Est. -
P/FCF -
EPS past 5Y -6.65%
ROI -34.55%
52W High -54.02%
Beta 1.93
Dividend TTM -
Quick Ratio 8.48
Sales past 5Y 87.14%
Gross Margin 71.22%
52W Low 149.08%
ATR (14) 0.44
Dividend Ex-Date -
Current Ratio 8.48
EPS Y/Y TTM 43.83%
Oper. Margin -299.86%
RSI (14) 27.25
Volatility 9.25% 8.01%
Employees 181
Debt/Eq 0.28
Sales Y/Y TTM -34.03%
Profit Margin -253.30%
Recom 2.56
Target Price 7.64
Option/Short Yes / Yes
LT Debt/Eq 0.26
EPS Q/Q 22.82%
Payout -
Rel Volume 0.76
Prev Close 4.10
Sales Surprise 8.97%
EPS Surprise 13.83%
Sales Q/Q -96.22%
Earnings Feb 26 AMC
Avg Volume 2.64M
Price 4.06
SMA20 -20.37%
SMA50 -36.63%
SMA200 0.00%
Trades
Volume 2,025,167
Change -0.98%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-27-23 Resumed
Wells Fargo
Equal Weight
$6
Jan-24-23 Downgrade
H.C. Wainwright
Buy → Neutral
$115 → $7
Jan-06-23 Downgrade
Wedbush
Outperform → Neutral
$42 → $7
Jan-06-23 Downgrade
Truist
Buy → Hold
$46 → $7
Jan-06-23 Downgrade
Stifel
Buy → Hold
$107 → $5.30
Jan-06-23 Downgrade
Piper Sandler
Overweight → Neutral
$71 → $12
Jan-06-23 Downgrade
Cowen
Outperform → Market Perform
Jan-06-23 Downgrade
BofA Securities
Buy → Underperform
$72 → $4
Jan-06-23 Downgrade
BMO Capital Markets
Outperform → Market Perform
$20 → $7
Jan-03-23 Downgrade
Guggenheim
Buy → Neutral
Dec-22-22 Downgrade
Oppenheimer
Outperform → Perform
Dec-15-22 Initiated
Goldman
Sell
$10
Nov-04-22 Resumed
Cantor Fitzgerald
Overweight
$98 → $45
Oct-10-22 Initiated
Canaccord Genuity
Buy
$42
Aug-18-22 Resumed
Wells Fargo
Overweight
$90
Jul-28-22 Initiated
Needham
Hold
Jul-11-22 Upgrade
BMO Capital Markets
Market Perform → Outperform
$50 → $47
Jun-03-22 Initiated
Robert W. Baird
Neutral
$28
Feb-11-22 Resumed
BMO Capital Markets
Market Perform
$50
Dec-15-21 Upgrade
Wedbush
Neutral → Outperform
Show Previous Ratings
May-03-24 04:30PM
Apr-22-24 04:30PM
Apr-06-24 02:17AM
Apr-04-24 11:30PM
Apr-03-24 08:00AM
04:01PM
Loading…
Apr-02-24 04:01PM
Mar-27-24 11:30AM
Mar-19-24 08:44AM
Mar-05-24 04:01PM
Mar-01-24 08:09AM
08:00AM
Feb-27-24 09:16AM
08:07AM
(Thomson Reuters StreetEvents)
Feb-26-24 05:10PM
04:35PM
04:08PM
Loading…
04:08PM
(Associated Press Finance)
04:01PM
Feb-21-24 09:21AM
Feb-19-24 10:00AM
Feb-15-24 08:00AM
Feb-02-24 04:01PM
Jan-30-24 07:54AM
Jan-29-24 02:53PM
Jan-08-24 08:00AM
Dec-22-23 12:00PM
Dec-18-23 02:58PM
Dec-13-23 05:00PM
Dec-08-23 11:30AM
Nov-09-23 01:18PM
Nov-08-23 06:18PM
04:08PM
Loading…
04:08PM
(Associated Press Finance)
04:01PM
Oct-25-23 08:00AM
Sep-15-23 06:01AM
Sep-07-23 11:30AM
Aug-31-23 08:00AM
Aug-29-23 07:30AM
Aug-09-23 12:12PM
11:04AM
(Thomson Reuters StreetEvents)
Aug-08-23 05:15PM
04:11PM
(Associated Press Finance)
04:01PM
Jul-28-23 08:00AM
Jul-22-23 08:35AM
Jul-01-23 10:33AM
Jun-16-23 03:53PM
Jun-14-23 06:42AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-04-23 08:27AM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-25-23 10:49AM
May-08-23 06:05AM
May-04-23 11:59AM
11:22AM
(Thomson Reuters StreetEvents)
May-03-23 05:15PM
04:11PM
04:01PM
12:00PM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
Apr-24-23 08:00AM
Apr-12-23 07:20AM
Mar-30-23 11:30AM
Mar-27-23 09:00AM
Mar-03-23 04:01PM
Mar-02-23 09:18PM
05:30AM
Mar-01-23 09:59AM
Feb-28-23 05:15PM
04:01PM
Feb-27-23 09:31AM
Feb-13-23 08:00AM
Feb-06-23 09:55AM
Feb-02-23 09:46AM
Jan-30-23 07:33AM
Jan-28-23 01:30PM
Jan-19-23 09:35AM
Jan-17-23 06:27AM
Jan-06-23 01:55PM
10:54AM
10:27AM
08:49AM
Jan-05-23 05:00PM
07:40AM
Jan-03-23 09:35AM
Jan-02-23 08:39AM
Dec-13-22 08:00AM
Dec-12-22 07:30AM
Dec-10-22 02:46PM
10:00AM
Nov-09-22 03:55PM
Nov-07-22 08:00AM
Nov-04-22 04:01PM
Nov-03-22 05:35PM
04:01PM
09:00AM
Nov-01-22 10:01AM
Oct-31-22 08:49AM
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dulac Edward J III Chief Financial Officer Mar 04 '24 Sale 7.77 2,447 19,013 101,479 Mar 05 04:24 PM Dulac Edward J III Chief Financial Officer Jan 29 '24 Sale 5.00 1,849 9,245 103,926 Jan 30 04:01 PM Wolchko J Scott President and CEO Jan 09 '24 Sale 4.37 14,391 62,889 371,248 Jan 10 04:29 PM Valamehr Bahram Chief R&D Officer Jan 09 '24 Sale 4.38 11,271 49,367 158,069 Jan 10 04:30 PM TAHL CINDY General Counsel and Secretary Jan 09 '24 Sale 4.37 10,874 47,519 142,361 Jan 10 04:30 PM Dulac Edward J III Chief Financial Officer Jan 09 '24 Sale 4.37 7,028 30,712 105,775 Jan 10 04:29 PM Dulac Edward J III Chief Financial Officer Jan 02 '24 Sale 3.66 5,182 18,966 112,803 Jan 03 04:03 PM Redmile Group, LLC Director Dec 26 '23 Buy 3.72 44,630 166,024 13,180,388 Dec 28 09:30 PM Dulac Edward J III Chief Financial Officer Dec 18 '23 Sale 3.50 1,585 5,548 117,985 Dec 19 04:01 PM TAHL CINDY General Counsel and Secretary Nov 09 '23 Sale 2.40 24,363 58,471 153,235 Nov 13 04:01 PM Dulac Edward J III Chief Financial Officer Aug 18 '23 Sale 2.80 4,718 13,210 119,570 Aug 21 04:02 PM Xu Yuan Director Aug 04 '23 Sale 3.71 632 2,345 9,302 Aug 07 04:01 PM Dulac Edward J III Chief Financial Officer Jul 05 '23 Sale 4.83 5,182 25,029 124,288 Jul 06 05:18 PM Powl Brian T. Chief Commercial Officer Jul 05 '23 Sale 4.87 3,854 18,769 41,146 Jul 06 05:19 PM Xu Yuan Director Jun 14 '23 Sale 5.58 3,460 19,307 9,934 Jun 15 04:05 PM
Index -
P/E -
EPS (ttm) -0.44
Insider Own 10.23%
Shs Outstand 48.61M
Perf Week -4.91%
Market Cap 132.71M
Forward P/E -
EPS next Y -0.34
Insider Trans 27.11%
Shs Float 43.96M
Perf Month -35.17%
Income -19.17M
PEG -
EPS next Q -0.13
Inst Own 75.20%
Short Float 2.82%
Perf Quarter -39.10%
Sales 44.85M
P/S 2.96
EPS this Y -13.64%
Inst Trans 0.68%
Short Ratio 3.32
Perf Half Y -38.41%
Book/sh 0.48
P/B 5.65
EPS next Y 32.50%
ROA -38.21%
Short Interest 1.24M
Perf Year -11.15%
Cash/sh 0.95
P/C 2.86
EPS next 5Y -
ROE -154.68%
52W Range 2.50 - 6.25
Perf YTD -53.68%
Dividend Est. -
P/FCF -
EPS past 5Y 62.58%
ROI -44.92%
52W High -56.64%
Beta 0.53
Dividend TTM -
Quick Ratio 2.41
Sales past 5Y 33.97%
Gross Margin 47.99%
52W Low 8.40%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 2.41
EPS Y/Y TTM 32.17%
Oper. Margin -41.86%
RSI (14) 30.59
Volatility 6.00% 6.99%
Employees 1430
Debt/Eq 1.11
Sales Y/Y TTM 45.01%
Profit Margin -42.74%
Recom 1.00
Target Price 6.10
Option/Short Yes / Yes
LT Debt/Eq 0.83
EPS Q/Q 38.77%
Payout -
Rel Volume 0.65
Prev Close 2.66
Sales Surprise 1.77%
EPS Surprise 7.69%
Sales Q/Q 44.90%
Earnings May 13 AMC
Avg Volume 372.50K
Price 2.71
SMA20 -16.83%
SMA50 -26.72%
SMA200 -41.79%
Trades
Volume 242,897
Change 1.88%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-03-24 Resumed
B. Riley Securities
Buy
$5.50
Dec-15-23 Initiated
Evercore ISI
In-line
$6
May-03-24 07:00AM
Apr-30-24 07:00AM
Apr-25-24 04:05PM
Apr-24-24 07:00AM
Apr-19-24 06:00AM
02:05AM
Loading…
Apr-12-24 02:05AM
Apr-10-24 01:51AM
Apr-09-24 07:00AM
Apr-05-24 02:42AM
Apr-04-24 07:00AM
01:56AM
Apr-02-24 08:35AM
Mar-20-24 10:13AM
Mar-19-24 06:41AM
(Thomson Reuters StreetEvents) +18.92%
Mar-18-24 08:53PM
05:31PM
Loading…
05:31PM
04:01PM
Mar-14-24 07:04AM
Mar-12-24 07:00AM
Mar-08-24 07:00AM
Feb-27-24 07:00AM
Feb-13-24 07:00AM
Jan-22-24 04:15PM
Jan-16-24 07:00AM
Jan-05-24 08:00AM
Dec-22-23 07:00AM
Dec-13-23 10:29AM
Nov-21-23 07:00AM
Nov-16-23 08:51AM
12:15AM
04:02PM
Loading…
Nov-15-23 04:02PM
Nov-10-23 09:55AM
08:50AM
Nov-07-23 09:55AM
Nov-06-23 05:10PM
04:02PM
Oct-30-23 07:00AM
Oct-20-23 08:02AM
Oct-12-23 07:59AM
Oct-09-23 08:50AM
Oct-05-23 07:15AM
07:00AM
Sep-27-23 07:00AM
Sep-25-23 07:54AM
Sep-22-23 06:39AM
Sep-21-23 08:50AM
07:00AM
Sep-20-23 07:22AM
Sep-12-23 09:40AM
Sep-06-23 07:00AM
Sep-05-23 08:50AM
Sep-04-23 09:55AM
Aug-24-23 09:40AM
07:00AM
Aug-18-23 07:00AM
Aug-16-23 09:55AM
08:50AM
Aug-09-23 09:25AM
Aug-08-23 03:27PM
Aug-07-23 05:50PM
04:02PM
Jul-28-23 07:00AM
Jul-12-23 08:29AM
Jul-10-23 08:42AM
Jul-07-23 11:04AM
Jun-29-23 08:50AM
Jun-16-23 09:40AM
Jun-14-23 07:05AM
Jun-12-23 07:00AM
May-31-23 09:40AM
May-19-23 08:24AM
May-12-23 08:15AM
07:00AM
May-08-23 07:00AM
May-05-23 01:34PM
Apr-28-23 06:47PM
06:47PM
Apr-20-23 06:31AM
06:30AM
Mar-29-23 07:27AM
Mar-27-23 07:00AM
Mar-16-23 07:00AM
Mar-07-23 07:00AM
Mar-01-23 08:00AM
Feb-16-23 07:00AM
Jan-18-23 04:05PM
Jan-09-23 07:00AM
Dec-25-22 12:07PM
Nov-23-22 04:05PM
Nov-16-22 08:00AM
Nov-14-22 04:05PM
Nov-07-22 08:00AM
Oct-04-22 08:00AM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-30-22 04:05PM
Aug-17-22 04:05PM
Aug-08-22 04:05PM
04:01PM
Aug-03-22 08:00AM
Augmedix, Inc. engages in the development of software that converts natural clinician-patient conversations into medical documentation. It offers live support including referrals, orders, and reminders that allow clinicians to focus on patient care. The company was founded by Ian Shakil in 2012 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Shakil Ian CHIEF STRATEGY OFFICER Apr 15 '24 Option Exercise 0.86 500 430 3,500 Apr 16 09:07 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 15 '24 Sale 3.80 500 1,900 3,000 Apr 16 09:07 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 12 '24 Option Exercise 0.86 19,544 16,808 22,544 Apr 15 09:15 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 12 '24 Sale 3.82 19,544 74,590 3,000 Apr 15 09:15 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 11 '24 Option Exercise 0.86 24,778 21,309 27,778 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 11 '24 Sale 3.93 24,778 97,477 3,000 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 10 '24 Option Exercise 0.86 36,467 31,362 39,467 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 10 '24 Sale 3.87 36,467 141,288 3,000 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 09 '24 Option Exercise 0.76 31,542 23,968 34,542 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 09 '24 Sale 4.14 31,542 130,521 3,000 Apr 11 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 08 '24 Option Exercise 0.64 28,563 18,280 40,780 Apr 09 08:49 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 08 '24 Sale 3.97 37,780 149,968 3,000 Apr 09 08:49 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 05 '24 Sale 4.03 51,387 207,233 12,217 Apr 09 08:49 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 04 '24 Sale 4.15 64,055 265,854 31,610 Apr 04 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 03 '24 Sale 4.11 45,906 188,600 95,665 Apr 04 08:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 02 '24 Sale 3.89 38,463 149,725 141,571 Apr 03 09:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 01 '24 Option Exercise 0.64 51,346 32,861 239,012 Apr 03 09:30 PM Shakil Ian CHIEF STRATEGY OFFICER Apr 01 '24 Sale 3.91 58,978 230,384 180,034 Apr 03 09:30 PM Shakil Ian CHIEF STRATEGY OFFICER Mar 28 '24 Sale 4.06 31,994 129,851 187,666 Apr 01 08:28 PM Ginocchio Paul CHIEF FINANCIAL OFFICER Nov 22 '23 Buy 4.85 10,000 48,500 128,000 Nov 27 07:00 AM Redmile Group, LLC Director Nov 20 '23 Buy 4.00 750,000 3,000,000 16,404,017 Nov 22 04:15 PM Redmile Group, LLC Director Nov 20 '23 Buy 4.00 750,000 3,000,000 9,446,146 Nov 22 04:15 PM Traylor Margie L. Director Jun 14 '23 Buy 4.51 26,530 119,649 47,331 Jun 16 05:50 PM Traylor Margie L. Director May 15 '23 Option Exercise 2.20 10,182 22,400 20,801 May 17 07:00 PM
Index RUT
P/E -
EPS (ttm) -4.82
Insider Own 64.57%
Shs Outstand 33.18M
Perf Week 7.13%
Market Cap 593.63M
Forward P/E -
EPS next Y -2.81
Insider Trans 2.32%
Shs Float 20.89M
Perf Month 13.27%
Income -246.42M
PEG -
EPS next Q -0.81
Inst Own 38.36%
Short Float 25.12%
Perf Quarter -12.36%
Sales 2.13M
P/S 278.70
EPS this Y 33.23%
Inst Trans -0.70%
Short Ratio 18.04
Perf Half Y 139.76%
Book/sh 3.46
P/B 2.91
EPS next Y 10.79%
ROA -52.60%
Short Interest 5.25M
Perf Year -18.46%
Cash/sh 5.74
P/C 1.75
EPS next 5Y -
ROE -100.48%
52W Range 3.81 - 17.70
Perf YTD 21.18%
Dividend Est. -
P/FCF -
EPS past 5Y -44.65%
ROI -103.58%
52W High -43.11%
Beta 0.26
Dividend TTM -
Quick Ratio 8.18
Sales past 5Y 19.85%
Gross Margin -413.85%
52W Low 164.30%
ATR (14) 0.92
Dividend Ex-Date -
Current Ratio 8.18
EPS Y/Y TTM 10.38%
Oper. Margin -12369.06%
RSI (14) 58.17
Volatility 7.84% 10.56%
Employees 224
Debt/Eq 0.20
Sales Y/Y TTM 99.25%
Profit Margin -11568.83%
Recom 1.89
Target Price 21.22
Option/Short Yes / Yes
LT Debt/Eq 0.17
EPS Q/Q 14.63%
Payout -
Rel Volume 0.62
Prev Close 9.43
Sales Surprise -6.93%
EPS Surprise 0.11%
Sales Q/Q 75.00%
Earnings Mar 07 AMC
Avg Volume 290.80K
Price 10.07
SMA20 17.77%
SMA50 0.74%
SMA200 18.12%
Trades
Volume 182,448
Change 6.79%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-09-24 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$9 → $21
Dec-15-23 Downgrade
BofA Securities
Buy → Neutral
$8
Dec-07-23 Downgrade
H.C. Wainwright
Buy → Neutral
$11 → $7
Nov-09-22 Resumed
Jefferies
Buy
$61 → $55
Oct-17-22 Initiated
JP Morgan
Neutral
$27
Aug-29-22 Initiated
BofA Securities
Buy
$34
Dec-13-21 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$51
Nov-05-21 Upgrade
Wedbush
Neutral → Outperform
Aug-26-21 Initiated
Morgan Stanley
Overweight
$100
Jan-29-21 Initiated
RBC Capital Mkts
Outperform
$121
Jan-19-21 Reiterated
H.C. Wainwright
Buy
$88 → $114
Dec-22-20 Downgrade
Wedbush
Outperform → Neutral
Jul-17-20 Initiated
Robert W. Baird
Outperform
$90
Jul-01-20 Initiated
H.C. Wainwright
Buy
$88
May-28-20 Initiated
SunTrust
Buy
$86
Apr-22-20 Initiated
Wedbush
Outperform
$73
Oct-14-19 Initiated
Stifel
Buy
$32
Oct-14-19 Initiated
Piper Jaffray
Overweight
$26
Oct-14-19 Initiated
Jefferies
Buy
$25
Oct-14-19 Initiated
Guggenheim
Buy
$30
Show Previous Ratings
May-03-24 10:00AM
Apr-30-24 12:00PM
Apr-17-24 08:30AM
Apr-10-24 07:00AM
Mar-07-24 10:52PM
05:45PM
Loading…
05:45PM
04:10PM
Mar-01-24 09:55AM
Feb-14-24 09:55AM
Feb-01-24 07:00AM
Jan-16-24 08:38AM
Jan-03-24 07:00AM
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
05:32AM
Loading…
Dec-01-23 05:32AM
Nov-27-23 03:52AM
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
Oct-05-23 07:29AM
Oct-03-23 04:05PM
Sep-20-23 04:36AM
07:00AM
Loading…
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
09:05AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
04:10PM
Jul-04-22 02:04PM
Jun-01-22 07:00AM
May-20-22 12:07PM
May-10-22 07:00AM
May-09-22 04:16PM
May-06-22 07:00AM
Apr-09-22 09:35AM
Apr-06-22 04:39PM
Apr-05-22 04:56PM
Mar-30-22 03:06PM
02:14PM
01:29PM
11:57AM
12:56AM
Mar-29-22 11:41AM
09:00AM
08:54AM
07:59AM
07:41AM
06:01AM
02:00AM
Feb-09-22 03:34PM
07:00AM
Feb-03-22 04:05PM
Jan-10-22 10:00AM
Jan-05-22 07:00AM
Dec-13-21 09:43AM
07:08AM
Dec-11-21 01:31PM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BAKER BROS. ADVISORS LP Director Mar 28 '24 Buy 9.62 97,473 937,632 3,753,480 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 27 '24 Buy 9.24 27,844 257,170 3,664,073 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 26 '24 Buy 8.26 270,000 2,230,767 3,638,533 Mar 28 07:04 PM Schwarzer Fred CEO AND PRESIDENT Mar 14 '24 Sale 10.17 4,182 42,533 216,651 Mar 15 07:51 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 14 '24 Sale 10.17 2,543 25,864 90,418 Mar 15 07:53 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 14 '24 Sale 10.17 2,535 25,782 94,388 Mar 15 07:55 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 14 '24 Sale 10.17 1,844 18,754 171,856 Mar 15 07:49 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 14 '24 Sale 10.17 1,578 16,049 61,006 Mar 15 07:48 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 14 '24 Sale 10.17 464 4,719 26,507 Mar 15 07:57 PM Schwarzer Fred CEO AND PRESIDENT Mar 13 '24 Sale 9.88 4,765 47,055 220,833 Mar 15 07:51 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 13 '24 Sale 9.88 2,897 28,608 92,961 Mar 15 07:53 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 13 '24 Sale 9.88 2,889 28,529 96,923 Mar 15 07:55 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 13 '24 Sale 9.88 2,101 20,748 173,700 Mar 15 07:49 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 13 '24 Sale 9.88 1,798 17,756 62,584 Mar 15 07:48 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 13 '24 Sale 9.88 529 5,224 26,971 Mar 15 07:57 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 01 '24 Option Exercise 0.93 3,026 2,814 4,039 Mar 05 07:34 PM BAKER BROS. ADVISORS LP Director Dec 15 '23 Buy 6.55 288,007 1,887,531 3,390,323 Dec 15 05:32 PM BAKER BROS. ADVISORS LP Director Dec 14 '23 Buy 6.50 157,370 1,023,157 3,123,585 Dec 15 05:32 PM BAKER BROS. ADVISORS LP Director Dec 13 '23 Buy 5.96 87,316 520,776 2,977,836 Dec 15 05:32 PM Schwarzer Fred CEO and President Dec 13 '23 Sale 5.78 17,576 101,558 102,848 Dec 15 07:20 PM Keyt Bruce Chief Scientific Officer Dec 13 '23 Sale 5.78 7,574 43,764 129,551 Dec 15 07:19 PM Decker Lisa Lynn Chief Business Officer Dec 13 '23 Sale 5.78 4,369 25,245 35,632 Dec 15 07:18 PM Takimoto Chris H Chief Medical Officer Nov 29 '23 Sale 6.21 1,180 7,331 53,562 Dec 01 07:03 PM Decker Lisa Lynn Chief Business Officer Nov 29 '23 Sale 6.21 1,180 7,331 40,001 Dec 01 07:01 PM Gauthier George Chief Commercial Officer Nov 29 '23 Sale 6.21 1,180 7,331 39,642 Dec 01 07:02 PM Tahir Misbah Chief Financial Officer Nov 27 '23 Sale 5.06 1,337 6,764 49,608 Nov 29 08:49 PM Schwarzer Fred CEO and President Nov 27 '23 Sale 5.06 1,337 6,764 120,424 Nov 29 08:48 PM Keyt Bruce Chief Scientific Officer Nov 27 '23 Sale 5.06 933 4,720 137,125 Nov 29 08:47 PM Gauthier George Chief Commercial Officer Oct 02 '23 Sale 7.95 935 7,430 39,082 Oct 03 07:55 PM Gauthier George Chief Commercial Officer Jul 03 '23 Sale 9.42 936 8,818 40,017 Jul 05 09:08 PM Topsoe Jakob Haldor Director Jun 30 '23 Buy 9.25 3,500 32,375 81,644 Jul 03 06:46 PM Topsoe Christina Teng Director Jun 30 '23 Buy 9.32 3,000 27,957 9,800 Jul 05 09:07 PM Redmile Group, LLC Director Jun 29 '23 Buy 9.42 80,423 757,585 2,974,186 Jul 03 09:45 PM Topsoe Jakob Haldor Director Jun 29 '23 Buy 9.10 3,500 31,846 78,144 Jul 03 06:46 PM Redmile Group, LLC Director Jun 29 '23 Sale 9.42 80,423 757,585 2,893,763 Jul 03 09:45 PM BEHRENS M KATHLEEN Director Jun 26 '23 Buy 8.00 112,500 900,000 330,700 Jun 28 07:34 PM Gauthier George Chief Commercial Officer May 23 '23 Sale 12.31 1,259 15,497 40,953 May 25 07:20 PM Decker Lisa Lynn Chief Business Officer May 23 '23 Sale 12.31 1,259 15,497 41,181 May 25 07:20 PM Tahir Misbah Chief Financial Officer May 23 '23 Sale 12.31 1,259 15,497 50,711 May 25 07:23 PM Takimoto Chris H Chief Medical Officer May 23 '23 Sale 12.31 1,259 15,497 54,742 May 25 07:24 PM Schwarzer Fred CEO and President May 23 '23 Sale 12.31 1,259 15,497 121,761 May 25 07:22 PM Keyt Bruce Chief Scientific Officer May 23 '23 Sale 12.31 982 12,088 138,058 May 25 07:21 PM
Index RUT
P/E -
EPS (ttm) -1.79
Insider Own 7.41%
Shs Outstand 70.12M
Perf Week 11.38%
Market Cap 655.78M
Forward P/E -
EPS next Y -0.63
Insider Trans -0.76%
Shs Float 66.07M
Perf Month -4.76%
Income -125.97M
PEG -
EPS next Q -0.41
Inst Own 91.77%
Short Float 7.64%
Perf Quarter -16.36%
Sales 50.46M
P/S 13.00
EPS this Y 29.64%
Inst Trans -0.52%
Short Ratio 8.44
Perf Half Y 31.05%
Book/sh 6.15
P/B 1.50
EPS next Y 47.74%
ROA -21.82%
Short Interest 5.05M
Perf Year 8.88%
Cash/sh 4.84
P/C 1.90
EPS next 5Y 11.00%
ROE -27.64%
52W Range 6.01 - 13.14
Perf YTD -11.45%
Dividend Est. -
P/FCF -
EPS past 5Y -6.52%
ROI -27.44%
52W High -29.98%
Beta 1.19
Dividend TTM -
Quick Ratio 6.92
Sales past 5Y 264.10%
Gross Margin 66.87%
52W Low 52.95%
ATR (14) 0.43
Dividend Ex-Date -
Current Ratio 6.92
EPS Y/Y TTM -168.88%
Oper. Margin -294.42%
RSI (14) 50.36
Volatility 5.79% 4.30%
Employees 277
Debt/Eq 0.06
Sales Y/Y TTM -88.69%
Profit Margin -249.63%
Recom 1.75
Target Price 13.53
Option/Short Yes / Yes
LT Debt/Eq 0.05
EPS Q/Q -14.52%
Payout -
Rel Volume 0.90
Prev Close 9.00
Sales Surprise -42.74%
EPS Surprise -30.43%
Sales Q/Q -71.81%
Earnings May 02 AMC
Avg Volume 598.37K
Price 9.20
SMA20 3.62%
SMA50 -9.86%
SMA200 3.93%
Trades
Volume 655,723
Change 2.22%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-21-23 Resumed
Wells Fargo
Overweight
$12
Jan-04-23 Reiterated
H.C. Wainwright
Neutral
$10 → $8
Dec-20-22 Upgrade
Jefferies
Hold → Buy
$7.70 → $11
Nov-01-22 Downgrade
H.C. Wainwright
Buy → Neutral
$40 → $8
Oct-21-22 Downgrade
SVB Leerink
Outperform → Mkt Perform
$8
Oct-04-22 Resumed
Wells Fargo
Overweight
$45 → $9
May-05-22 Upgrade
Guggenheim
Neutral → Buy
$14
Mar-15-22 Initiated
Evercore ISI
Outperform
$15
Dec-10-21 Upgrade
SVB Leerink
Mkt Perform → Outperform
Nov-17-21 Resumed
Guggenheim
Neutral
Oct-07-21 Initiated
Jefferies
Hold
$32
Mar-31-21 Initiated
Credit Suisse
Outperform
$55
Feb-25-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$41
Feb-08-21 Resumed
H.C. Wainwright
Buy
$57
Jan-25-21 Downgrade
Citigroup
Buy → Neutral
$50 → $53
Sep-29-20 Resumed
JP Morgan
Neutral
$48
Aug-06-20 Initiated
SVB Leerink
Outperform
$45
Jan-10-20 Initiated
Wolfe Research
Outperform
$61
Dec-09-19 Initiated
JP Morgan
Neutral
Nov-25-19 Initiated
H.C. Wainwright
Buy
$65
Show Previous Ratings
May-02-24 04:05PM
Apr-30-24 06:00AM
Apr-11-24 06:00AM
Apr-10-24 09:35AM
Apr-08-24 06:00AM
06:00AM
Loading…
Mar-28-24 06:00AM
Mar-27-24 06:00AM
Mar-22-24 12:00PM
Mar-11-24 12:44PM
Mar-09-24 01:09PM
Mar-07-24 06:39AM
(FierceBiotech.com) -6.46%
Mar-06-24 10:53PM
04:09PM
Mar-05-24 04:30PM
Feb-28-24 10:00AM
06:00AM
Loading…
Feb-27-24 06:00AM
Feb-14-24 06:00AM
Feb-09-24 08:00AM
Feb-08-24 06:00AM
Jan-31-24 06:00AM
Jan-11-24 12:00PM
Jan-04-24 06:15AM
06:00AM
Dec-26-23 08:00AM
Dec-15-23 08:30AM
Dec-08-23 10:11AM
Nov-30-23 08:30AM
Nov-08-23 05:33PM
Nov-07-23 04:05PM
Nov-01-23 08:30AM
08:30AM
Loading…
Oct-17-23 08:30AM
Oct-16-23 04:30PM
Aug-10-23 04:05PM
Aug-01-23 08:30AM
Jul-19-23 08:30AM
Jul-03-23 08:30AM
Jun-29-23 04:05PM
Jun-26-23 08:30AM
Jun-02-23 06:41PM
Jun-01-23 08:30AM
May-18-23 08:30AM
May-08-23 04:05PM
May-01-23 08:30AM
Apr-18-23 04:05PM
Apr-17-23 08:30AM
Apr-10-23 08:30AM
Apr-03-23 08:30AM
Mar-14-23 04:30PM
Mar-07-23 04:05PM
Feb-28-23 08:30AM
Feb-21-23 08:30AM
Jan-25-23 08:30AM
Jan-19-23 07:45AM
Jan-04-23 04:15PM
Dec-21-22 07:30AM
07:30AM
Dec-19-22 07:00AM
Dec-14-22 04:15PM
Dec-09-22 08:00AM
Dec-05-22 08:30AM
Nov-29-22 08:30AM
Nov-24-22 12:20PM
Nov-22-22 09:55AM
08:30AM
Nov-21-22 12:22PM
09:55AM
09:00AM
Nov-08-22 05:45PM
04:22PM
Nov-02-22 10:00AM
Nov-01-22 10:01AM
Oct-31-22 04:42PM
Oct-21-22 01:35PM
Oct-20-22 01:36PM
11:48AM
08:30AM
Oct-19-22 11:08AM
08:38AM
07:29AM
06:07AM
06:00AM
Oct-18-22 08:30AM
Oct-13-22 07:00AM
Oct-07-22 04:15PM
Oct-04-22 08:30AM
Oct-03-22 08:30AM
Sep-29-22 07:30AM
Sep-26-22 04:15PM
Sep-16-22 08:30AM
Sep-13-22 09:34AM
Sep-08-22 04:15PM
Sep-04-22 06:05PM
Aug-04-22 08:35PM
04:15PM
Aug-01-22 08:30AM
Jul-27-22 08:45AM
Jul-25-22 08:30AM
Jul-22-22 08:30AM
Jul-21-22 08:30AM
Jul-15-22 08:00AM
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Galbraith Kenneth Chair & CEO Jan 08 '24 Sale 11.22 5,706 63,996 23,762 Jan 08 06:23 PM Moore Paul Andrew Chief Scientific Officer Jan 08 '24 Sale 11.22 2,339 26,233 7,367 Jan 08 06:01 PM Astle Christopher SVP & Chief Financial Officer Jan 08 '24 Sale 11.22 1,431 16,050 6,503 Jan 08 06:14 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '24 Option Exercise 0.00 17,166 0 17,166 Jan 08 06:01 PM Galbraith Kenneth Chair & CEO Jan 05 '24 Option Exercise 0.00 47,666 0 47,666 Jan 08 06:23 PM Astle Christopher SVP & Chief Financial Officer Jan 05 '24 Option Exercise 0.00 10,500 0 12,497 Jan 08 06:14 PM Galbraith Kenneth Chair & CEO Jan 05 '24 Sale 10.65 18,198 193,849 29,468 Jan 08 06:23 PM Moore Paul Andrew Chief Scientific Officer Jan 05 '24 Sale 10.65 7,460 79,465 9,706 Jan 08 06:01 PM Astle Christopher SVP & Chief Financial Officer Jan 05 '24 Sale 10.65 4,563 48,606 7,934 Jan 08 06:14 PM Astle Christopher SVP & Chief Financial Officer Dec 11 '23 Option Exercise 0.00 1,550 0 2,883 Dec 11 08:00 PM Astle Christopher SVP & Chief Financial Officer Dec 11 '23 Sale 9.13 886 8,089 1,997 Dec 11 08:00 PM EcoR1 Capital, LLC 10% Owner Jun 16 '23 Buy 8.12 3,350,000 27,202,000 13,437,473 Jun 21 04:04 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite